Research output

Research output per year 1989 2002 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2024

• 248 Article
• 35 Review article
• 21 Letter
• 6 Comment/debate
• 4 More
  • 2 Chapter
  • 1 Book
  • 1 Conference contribution

Research output per year

Research output per year

Search results

• 2024

  Day 100 Natural Killer Cell/CD14+HLA-DR^DIM ratio and survival in lymphoma post-autologous peripheral blood hematopoietic stem cell transplantation

  Porrata, L. F., Ansell, S. M., Micallef, I., Johnston, P. B., Villasboas Bisneto, J., Paludo, J., Durani, U. & Markovic, S. N., Jan 2024, In: Clinical Transplantation. 38, 1, e15211.

  Research output: Contribution to journal › Article › peer-review

  • Peripheral Blood Stem Cell Transplantation 100%
  • Hematopoietic Stem Cell Transplantation 80%
  • Natural Killer Cells 69%
  • Lymphoma 62%
  • Progression-Free Survival 48%

• International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

  Kuan, E. C., Wang, E. W., Adappa, N. D., Beswick, D. M., London, N. R., Su, S. Y., Wang, M. B., Abuzeid, W. M., Alexiev, B., Alt, J. A., Antognoni, P., Alonso-Basanta, M., Batra, P. S., Bhayani, M., Bell, D., Bernal-Sprekelsen, M., Betz, C. S., Blay, J. Y., Bleier, B. S., Bonilla-Velez, J., & 139 othersCallejas, C., Carrau, R. L., Casiano, R. R., Castelnuovo, P., Chandra, R. K., Chatzinakis, V., Chen, S. B., Chiu, A. G., Choby, G., Chowdhury, N. I., Citardi, M. J., Cohen, M. A., Dagan, R., Dalfino, G., Dallan, I., Dassi, C. S., de Almeida, J., Dei Tos, A. P., DelGaudio, J. M., Ebert, C. S., El-Sayed, I. H., Eloy, J. A., Evans, J. J., Fang, C. H., Farrell, N. F., Ferrari, M., Fischbein, N., Folbe, A., Fokkens, W. J., Fox, M. G., Lund, V. J., Gallia, G. L., Gardner, P. A., Geltzeiler, M., Georgalas, C., Getz, A. E., Govindaraj, S., Gray, S. T., Grayson, J. W., Gross, B. A., Grube, J. G., Guo, R., Ha, P. K., Halderman, A. A., Hanna, E. Y., Harvey, R. J., Hernandez, S. C., Holtzman, A. L., Hopkins, C., Huang, Z., Huang, Z., Humphreys, I. M., Hwang, P. H., Iloreta, A. M., Ishii, M., Ivan, M. E., Jafari, A., Kennedy, D. W., Khan, M., Kimple, A. J., Kingdom, T. T., Knisely, A., Kuo, Y. J., Lal, D., Lamarre, E. D., Lan, M. Y., Le, H., Lechner, M., Lee, N. Y., Lee, J. K., Lee, V. H., Levine, C. G., Lin, J. C., Lin, D. T., Lobo, B. C., Locke, T., Luong, A. U., Magliocca, K. R., Markovic, S. N., Matnjani, G., McKean, E. L., Meço, C., Mendenhall, W. M., Michel, L., Na'ara, S., Nicolai, P., Nuss, D. W., Nyquist, G. G., Oakley, G. M., Omura, K., Orlandi, R. R., Otori, N., Papagiannopoulos, P., Patel, Z. M., Pfister, D. G., Phan, J., Psaltis, A. J., Rabinowitz, M. R., Ramanathan, M., Rimmer, R., Rosen, M. R., Sanusi, O., Sargi, Z. B., Schafhausen, P., Schlosser, R. J., Sedaghat, A. R., Senior, B. A., Shrivastava, R., Sindwani, R., Smith, T. L., Smith, K. A., Snyderman, C. H., Solares, C. A., Sreenath, S. B., Stamm, A., Stölzel, K., Sumer, B., Surda, P., Tajudeen, B. A., Thompson, L. D. R., Thorp, B. D., Tong, C. C. L., Tsang, R. K., Turner, J. H., Turri-Zanoni, M., Udager, A. M., van Zele, T., VanKoevering, K., Welch, K. C., Wise, S. K., Witterick, I. J., Won, T. B., Wong, S. N., Woodworth, B. A., Wormald, P. J., Yao, W. C., Yeh, C. F., Zhou, B. & Palmer, J. N., Feb 2024, In: International Forum of Allergy and Rhinology. 14, 2, p. 149-608 460 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Hypersensitivity 100%
  • Neoplasms 39%
  • Publications 12%
  • Patient Care 11%
  • Meta-Analysis 11%

• Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial

  Hieken, T. J., Nelson, G. D., Flotte, T. J., Grewal, E. P., Chen, J., McWilliams, R. R., Kottschade, L. A., Yang, L., Domingo-Musibay, E., Dronca, R. S., Yan, Y., Markovic, S. N., Dimou, A., Montane, H. N., Erskine, C. L., Piltin, M. A., Price, D. L., Khariwala, S. S., Hui, J., Strand, C. A., & 4 othersHarrington, S. M., Suman, V. J., Dong, H. & Block, M. S., Dec 2024, In: Nature communications. 15, 1, 1430.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cobimetinib 100%
  • Vemurafenib 85%
  • atezolizumab 73%
  • Melanoma 38%
  • Lymph Node Excision 30%

• Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors

  Smith, K. E. R. & Markovic, S. N., Jan 1 2024, In: Clinical chemistry. 70, 1, p. 25-26 2 p.

  Research output: Contribution to journal › Article › peer-review

• Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma

  Sener, U., Webb, M., Breen, W. G., Neth, B. J., Laack, N. N., Routman, D., Brown, P. D., Mahajan, A., Frechette, K., Dudek, A. Z., Markovic, S. N., Block, M. S., McWilliams, R. R., Dimou, A., Kottschade, L. A., Montane, H. N., Kizilbash, S. H. & Campian, J. L., Feb 2024, In: Journal of Immunotherapy and Precision Oncology. 7, 1, p. 1-6 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Craniospinal Irradiation 100%
  • Protons 65%
  • Immunotherapy 56%
  • Melanoma 53%
  • Nivolumab 37%
• 2023

  An Unexpected Diagnosis Uncovered by Quantitative Molecular Findings: A Case Report

  Buglioni, A., Guo, R., Rumilla, K. M., Edgar, M. A., Markovic, S. N. & Zheng, G., Aug 2023, In: JNCCN Journal of the National Comprehensive Cancer Network. 21, 8, p. 787-791 5 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Melanoma 100%
  • Langerhans Cell Histiocytosis 78%
  • High-Throughput Nucleotide Sequencing 57%
  • Polymerase Chain Reaction 35%
  • Limit of Detection 31%

• A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses

  Smith, K. E. R., Peng, K. W., Pulido, J. S., Weisbrod, A. J., Strand, C. A., Allred, J. B., Newsom, A. N., Zhang, L., Packiriswamy, N., Kottke, T., Tonne, J. M., Moore, M., Montane, H. N., Kottschade, L. A., McWilliams, R. R., Dudek, A. Z., Yan, Y., Dimou, A., Markovic, S. N., Federspiel, M. J., & 3 othersVile, R. G., Dronca, R. S. & Block, M. S., 2023, In: Frontiers in immunology. 14, 1279387.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Tyrosine Phenol-Lyase 100%
  • tyrosinase-related protein-1 79%
  • Oncolytic Viruses 68%
  • Uveal melanoma 65%
  • Vesicular Stomatitis 63%

• Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors

  Farooqui, N., Zaidi, M., Vaughan, L., McKee, T. D., Ahsan, E., Pavelko, K. D., Villasboas, J. C., Markovic, S., Taner, T., Leung, N., Dong, H., Alexander, M. P. & Herrmann, S. M., Mar 2023, In: Kidney International Reports. 8, 3, p. 628-641 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Acute Kidney Injury 100%
  • Cytokines 65%
  • Phenotype 63%
  • Tumor Necrosis Factor-alpha 29%
  • T-Lymphocytes 21%

• Cytokine Storm Due to Intralesional Intelukin-2 Therapy for Cutaneous In-Transit Melanoma

  Isaq, N. A., Brewer, J. D., Markovic, S. N., Montane, H. & Demer, A. M., Dec 1 2023, In: Dermatologic Surgery. 49, 12, p. 1198-1199 2 p.

  Research output: Contribution to journal › Article › peer-review

• Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia

  Cass, S. H., Tobin, J. W. D., Seo, Y. D., Gener-Ricos, G., Keung, E. Z., Burton, E. M., Davies, M. A., McQuade, J. L., Lazar, A. J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A. M., Carlino, M. S., Smith, J. L., & 13 othersMollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S. A., Markovic, S. N., Ding, W., Call, T. G., Hampel, P. J., Long, G. V., Wargo, J. A. & Ferrajoli, A., Sep 2023, In: Annals of Oncology. 34, 9, p. 796-805 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • B-Cell Chronic Lymphocytic Leukemia 100%
  • Melanoma 78%
  • Progression-Free Survival 18%
  • Therapeutics 15%
  • Survival 14%

• Melanoma-derived mediators can foster the premetastatic niche: crossroad to lymphatic metastasis

  Suman, S. & Markovic, S. N., Sep 2023, In: Trends in Immunology. 44, 9, p. 724-743 20 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Lymphatic Metastasis 100%
  • Melanoma 63%
  • Sentinel Lymph Node 55%
  • Immunity 37%
  • Neoplasms 24%

• Multiplex Immunofluorescence Image Quality Checking Using DAPI Channel–referenced Evaluation

  Jiang, J., Moore, R., Jordan, C. E., Guo, R., Maus, R. L., Liu, H., Goode, E., Markovic, S. N. & Wang, C., Mar 2023, In: Journal of Histochemistry and Cytochemistry. 71, 3, p. 121-130 10 p.

  Research output: Contribution to journal › Article › peer-review

  • 2-phenylindole 100%
  • Fluorescent Antibody Technique 53%
  • Data Accuracy 16%
  • Cell Nucleus 16%
  • Biomedical Research 15%

• Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas

  Coveler, A. L., Smith, D. C., Phillips, T., Curti, B. D., Goel, S., Mehta, A. N., Kuzel, T. M., Markovic, S. N., Rixe, O., Bajor, D. L., Gajewski, T. F., Gutierrez, M., Lee, H. J., Gopal, A. K., Caimi, P., Heath, E. I., Thompson, J. A., Ansari, S., Jacquemont, C., Topletz-Erickson, A., & 3 othersZhou, P., Schmitt, M. W. & Grilley-Olson, J. E., Jun 29 2023, In: Journal for ImmunoTherapy of Cancer. 11, 6, 005584.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Lymphoma 100%
  • Neoplasms 38%
  • Hypersensitivity 32%
  • Safety 23%
  • Pharmacokinetics 20%

• Sinonasal mucosal melanoma: An analysis of treatment-related adverse events and associated factors

  Johnson, B. J., Guo, R., Moore, E. J., Price, D. L., Van Abel, K. M., Van Gompel, J. J., Link, M. J., Peris-Celda, M., Stokken, J. K., Pinheiro-Neto, C., Kottschade, L., Markovic, S., Block, M., McWilliams, R., Montane, H., Dimou, A., Gergelis, K., Gamez, M. E. & Choby, G., Jun 2023, In: International Forum of Allergy and Rhinology. 13, 6, p. 1037-1041 5 p.

  Research output: Contribution to journal › Comment/debate › peer-review
• 2022

  BRAF V600E Expression in Primary Melanoma and Its Association With Death: A Population-Based, Retrospective, Cross-Sectional Study

  Harvey, J. A., Lehman, J. S., Lohse, C. M., Chamberlain, A. M., Markovic, S. N., Vachon, C. M. & Brewer, J. D., May 2022, In: Cutis. 109, 5

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Melanoma 100%
  • Cross-Sectional Studies 78%
  • Population 47%
  • Mutation 33%
  • Survival 33%

• Erratum: Maternal monocytes respond to cell-free fetal DNA and initiate key processes of human parturition (Journal of Immunology (2022) 207 (2433-2444) DOI: 10.4049/jimmunol.2100649)

  Kazemi, N. Y., Fedyshyn, B., Sutor, S., Fedyshyn, Y., Markovic, S. & Enninga, E. A. L., Nov 1 2022, In: Journal of Immunology. 209, 9, p. 1806 1 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • Allergy and Immunology 84%
  • Monocytes 65%
  • Color 65%
  • Parturition 55%

• Immune Checkpoint Inhibitor-Induced Hypophysitis: Lessons Learnt from a Large Cancer Cohort

  Kotwal, A., Rouleau, S. G., Dasari, S., Kottschade, L., Ryder, M., Kudva, Y. C., Markovic, S. & Erickson, D., Apr 2022, In: Journal of Investigative Medicine. 70, 4, p. 939-946 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Hypophysitis 100%
  • Ipilimumab 67%
  • Cell Death 65%
  • pembrolizumab 38%
  • Nivolumab 27%

• Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation

  Porrata, L. F., Inwards, D. J., Ansell, S. M., Micallef, I. N., Johnston, P. B., Villasboas, J. C., Paludo, J. & Markovic, S. N., 2022, In: Leukemia and Lymphoma. 63, 10, p. 2436-2443 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Autografts 100%
  • Lymphocyte Count 99%
  • Stem Cell Transplantation 96%
  • Lymphoma 76%
  • Peripheral Blood Stem Cell Transplantation 69%

• Mastocytosis and melanoma: a case series

  Rydberg, A., Lehman, J., Markovic, S. & Anderson, K., May 2022, In: International journal of dermatology. 61, 5, p. 603-606 4 p.

  Research output: Contribution to journal › Article › peer-review

• Merkel cell carcinoma of unknown primary: Clinical presentation and outcomes

  Broida, S. E., Chen, X. T., Baum, C. L., Brewer, J. D., Block, M. S., Jakub, J. W., Pockaj, B. A., Foote, R. L., Markovic, S. N., Hieken, T. J. & Houdek, M. T., Nov 2022, In: Journal of Surgical Oncology. 126, 6, p. 1080-1086 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Merkel Cell Carcinoma 100%
  • Recurrence 23%
  • Parotid Gland 23%
  • Lymph Node Excision 20%
  • Survival 17%

• NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy

  Wen, T., Barham, W., Li, Y., Zhang, H., Gicobi, J. K., Hirdler, J. B., Liu, X., Ham, H., Peterson Martinez, K. E., Lucien, F., Lavoie, R. R., Li, H., Correia, C., Monie, D. D., An, Z., Harrington, S. M., Wu, X., Guo, R., Dronca, R. S., Mansfield, A. S., & 9 othersYan, Y., Markovic, S. N., Park, S. S., Sun, J., Qin, H., Liu, M. C., Vasmatzis, G., Billadeau, D. D. & Dong, H., Feb 2022, In: Cancer Immunology Research. 10, 2, p. 162-181 20 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Natural Killer Cells 100%
  • Immunotherapy 94%
  • T-Lymphocytes 66%
  • Proteins 39%
  • Neoplasms 34%

• Quantitative spatial evaluation of tumor-immune interactions in the immunotherapy setting of metastatic melanoma lymph nodes

  Maus, R. L. G., Leontovich, A. A., Moore, R. M., Fogarty, Z., Guo, R., Davidson, T. M., Tekin, B., Atherton, C., Schimke, J. M., Dicke, B. A., Chen, B. J. & Markovic, S. N., Dec 5 2022, In: Frontiers in immunology. 13, 1024039.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Evaluation Studies 100%
  • Immunotherapy 98%
  • Melanoma 92%
  • Lymph Nodes 79%
  • Recurrence 47%

• Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy

  Davidson, T. M., Foster, N., Lucien, F., Markovic, S., Dong, H., Winters, J. L., Park, S. S. & Orme, J. J., May 12 2022, In: BMJ open. 12, 5, p. e050112

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Plasma Exchange 100%
  • Immunotherapy 72%
  • Melanoma 68%
  • Immunity 67%
  • Ligands 58%

• SAMCNet: Towards a Spatially Explainable AI Approach for Classifying MxIF Oncology Data

  Farhadloo, M., Molnar, C., Luo, G., Li, Y., Shekhar, S., Maus, R. L., Markovic, S., Leontovich, A. & Moore, R., Aug 14 2022, KDD 2022 - Proceedings of the 28th ACM SIGKDD Conference on Knowledge Discovery and Data Mining. Association for Computing Machinery, p. 2860-2870 11 p. (Proceedings of the ACM SIGKDD International Conference on Knowledge Discovery and Data Mining).

  Research output: Chapter in Book/Report/Conference proceeding › Conference contribution

  • Oncology 100%
  • Deep neural networks 72%
  • Artificial intelligence 65%
  • Ecology 46%
  • Network architecture 34%

• The immunologic balance: three cases of rituximab-associated melanoma

  Davidson, T. M., Markovic, S. N. & Dimou, A., Feb 1 2022, In: Melanoma research. 32, 1, p. 67-70 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Rituximab 100%
  • Melanoma 76%
  • Non-Hodgkin's Lymphoma 14%
  • Population 6%
  • Neoplasms 4%
• 2021

  A Novel Wearable Device for Continuous Temperature Monitoring Fever Detection

  Verma, N., Haji-Abolhassani, I., Ganesh, S., Vera-Aguilera, J., Paludo, J., Heitz, R., Markovic, S. N., Kulig, K. & Ghoreyshi, A., 2021, In: IEEE Journal of Translational Engineering in Health and Medicine. 9, 9490248.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Wearable technology 100%
  • Monitoring 50%
  • Temperature 35%
  • Stem cells 21%
  • Chemotherapy 11%

• Associations of Cutaneous Immune-Related Adverse Effects of Immunotherapy With Treatment Response in Patients With Metastatic Melanoma

  Kumar, A. B., Bryce, A. H., Vishnu, P., Markovic, S. N. & McEvoy, M. T., Mar 6 2021, In: SKIN: Journal of Cutaneous Medicine. 5, 2, p. 108-117 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Immunotherapy 100%
  • Melanoma 94%
  • Ipilimumab 79%
  • Nivolumab 77%
  • Skin 62%

• Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events

  Isik, B., Alexander, M. P., Manohar, S., Vaughan, L., Kottschade, L., Markovic, S., Lieske, J., Kukla, A., Leung, N. & Herrmann, S. M., Apr 2021, In: Kidney International Reports. 6, 4, p. 1022-1031 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Acute Kidney Injury 100%
  • Biomarkers 68%
  • Kidney 56%
  • Creatinine 41%
  • Urine 37%

• Cancer immune control dynamics: a clinical data driven model of systemic immunity in patients with metastatic melanoma

  Frisch, H. P., Sprau, A., McElroy, V. F., Turner, J. D., Becher, L. R. E., Nevala, W. K., Leontovich, A. A. & Markovic, S. N., Dec 2021, In: BMC bioinformatics. 22, 1, 197.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Melanoma 100%
  • Dynamic Control 93%
  • Biomarkers 85%
  • Immunity 83%
  • Data-driven 78%

• Extensive Perineural Spread of Subungual Melanoma

  Murthy, N. K., Broski, S. M., Amrami, K. K., Markovic, S. N. & Spinner, R. J., Jan 2021, In: World neurosurgery. 145, p. 98-101 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Melanoma 100%
  • Lower Extremity 27%
  • Peroneal Neuropathies 24%
  • Nivolumab 23%
  • Tibial Nerve 21%

• Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

  LoRusso, P. M., Sekulic, A., Sosman, J. A., Liang, W. S., Carpten, J., Craig, D. W., Solit, D. B., Bryce, A. H., Kiefer, J. A., Aldrich, J., Nasser, S., Halperin, R., Byron, S. A., Pilat, M. J., Boerner, S. A., Durecki, D., Hendricks, W. P. D., Enriquez, D., Izatt, T., Keats, J., & 27 othersLegendre, C., Markovic, S. N., Weise, A., Naveed, F., Schmidt, J., Basu, G. D., Sekar, S., Adkins, J., Tassone, E., Sivaprakasam, K., Zismann, V., Calvert, V. S., Petricoin, E. F., Fecher, L. A., Lao, C., Paul Eder, J., Vogelzang, N. J., Perlmutter, J., Gorman, M., Manica, B., Fox, L., Schork, N., Zelterman, D., DeVeaux, M., Joseph, R. W., Lance Cowey, C. & Trent, J. M., Apr 2021, In: PloS one. 16, 4 April, e0248097.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Genomics 100%
  • Melanoma 82%
  • Clinical Trials 64%
  • MEK162 30%
  • Mitogen-Activated Protein Kinase Kinases 17%

• Increased cell-free fetal DNA release after apoptosis and sterile inflammation in human trophoblast cells

  Kazemi, N. Y., Fedyshyn, B., Yelsa, I., Fedyshyn, Y., Ruano, R., Markovic, S. N., Chakraborty, R. & Enninga, E. A. L., Nov 2021, In: American Journal of Reproductive Immunology. 86, 5, e13483.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • Trophoblasts 86%
  • Apoptosis 48%
  • Inflammation 46%
  • HMGB1 Protein 42%

• Infused Autograft Absolute Lymphocyte Count Predicts Superior Survival in Diffuse Large B Cell Lymphoma Patients Post-Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation: A Matched Case-Control Study

  Porrata, L. F., Burgstaler, E. A., Winters, J. L., Jacob, E., Inwards, D. J., Ansell, S. M., Micallef, I. N., Johnston, P. B., Villasboas, J., Paludo, J. & Markovic, S. N., Sep 2021, In: Transplantation and Cellular Therapy. 27, 9, p. 769.e1-769.e8

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Peripheral Blood Stem Cell Transplantation 100%
  • Lymphoma, Large B-Cell, Diffuse 84%
  • Autografts 81%
  • Lymphocyte Count 81%
  • Hematopoietic Stem Cell Transplantation 80%

• Maternal Monocytes Respond to Cell-Free Fetal DNA and Initiate Key Processes of Human Parturition

  Kazemi, N. Y., Fedyshyn, B., Sutor, S., Fedyshyn, Y., Markovic, S. & Enninga, E. A. L., Nov 15 2021, In: Journal of Immunology. 207, 10, p. 2433-2444 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cell-Free Nucleic Acids 100%
  • Monocytes 65%
  • Parturition 55%
  • Mothers 50%
  • Pregnancy 23%

• Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence

  Slingluff, C. L., Lewis, K. D., Andtbacka, R., Hyngstrom, J., Milhem, M., Markovic, S. N., Bowles, T., Hamid, O., Hernandez-Aya, L., Claveau, J., Jang, S., Philips, P., Holtan, S. G., Shaheen, M. F., Curti, B., Schmidt, W., Butler, M. O., Paramo, J., Lutzky, J., Padmanabhan, A., & 25 othersThomas, S., Milton, D., Pecora, A., Sato, T., Hsueh, E., Badarinath, S., Keech, J., Kalmadi, S., Kumar, P., Weber, R., Levine, E., Berger, A., Bar, A., Beck, J. T., Travers, J. B., Mihalcioiu, C., Gastman, B., Beitsch, P., Rapisuwon, S., Glaspy, J., McCarron, E. C., Gupta, V., Behl, D., Blumenstein, B. & Peterkin, J. J., Oct 1 2021, In: Journal for ImmunoTherapy of Cancer. 9, 10, e003272.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Melanoma 100%
  • Vaccines 90%
  • Placebos 83%
  • Recurrence 69%
  • Melanoma-Specific Antigens 48%

• Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma

  Kankeu Fonkoua, L. A., Chakrabarti, S., Sonbol, M. B., Kasi, P. M., Starr, J. S., Liu, A. J., Nevala, W. K., Maus, R. L., Bois, M. C., Pitot, H. C., Chandrasekharan, C., Ross, H. J., Wu, T. T., Graham, R. P., Villasboas, J. C., Weiss, M., Foster, N. R., Markovic, S. N., Dong, H. & Yoon, H. H., Jul 15 2021, In: International Journal of Cancer. 149, 2, p. 378-386 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • ramucirumab 100%
  • Vascular Endothelial Growth Factor Receptor-2 87%
  • Paclitaxel 71%
  • Adenocarcinoma 55%
  • Progression-Free Survival 23%

• Percutaneous Image-Guided Thermal Ablation of Adrenal Metastasis from Melanoma: A Single-Institution Experience

  Jang, S., Eiken, P. W., Atwell, T. D., Markovic, S. N., Bancos, I. & Welch, B. T., Sep 2021, In: Journal of Vascular and Interventional Radiology. 32, 9, p. 1288-1291 4 p.

  Research output: Contribution to journal › Article › peer-review

  • Melanoma 100%
  • Hot Temperature 93%
  • Neoplasm Metastasis 74%
  • Length of Stay 45%
  • Survival 33%

• Progressive melanoma versus tumor melanosis: is imaging enough?

  Davidson, T. M., Markovic, S. N., Block, M. S. & Guo, R., Nov 2021, In: Annals of Oncology. 32, 11, p. 1449-1450 2 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Successful encorafenib desensitization in a patient with recurrent metastatic melanoma

  Cullen, G. D., Finnes, H. D., Markovic, S. N. & Volcheck, G. W., Aug 1 2021, In: Melanoma research. 31, 4, p. 402-404 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Immediate Hypersensitivity 45%
  • Melanoma 42%
  • Hypersensitivity 13%
  • Therapeutics 5%

• The role and clinical interest of extracellular vesicles in pregnancy and ovarian cancer

  Kazemi, N. Y., Gendrot, B., Berishvili, E., Markovic, S. N. & Cohen, M., Sep 2021, In: Biomedicines. 9, 9, 1257.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Extracellular Vesicles 100%
  • Ovarian Neoplasms 77%
  • Communication 77%
  • Marker 74%
  • Nucleic Acid 71%
• 2020

  Aberrant immunohistochemical expression of CD4 as a rare finding in metastatic melanoma

  Chatzopoulos, K., O'Brien, D. R., Sotiriou, S., Khazaie, K., Jen, J., Kocher, J. P. A., Markovic, S. N. & Flotte, T. J., Dec 2020, In: Journal of Cutaneous Pathology. 47, 12, p. 1223-1226 4 p.

  Research output: Contribution to journal › Letter › peer-review

• Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations

  DeLeon, T. T., Almquist, D. R., Kipp, B. R., Langlais, B. T., Mangold, A., Winters, J. L., Kosiorek, H. E., Joseph, R. W., Dronca, R. S., Block, M. S., McWilliams, R. R., Kottschade, L. A., Rumilla, K. M., Voss, J. S., Seetharam, M., Sekulic, A., Markovic, S. N. & Bryce, A. H., 2020, In: PloS one. 15, 3, e0230306.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Melanoma 100%
  • Health Care Outcome Assessment 78%
  • Mutation 67%
  • Disease Progression 41%
  • Survival 38%
  4 Scopus citations

• Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status with Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis

  Yang, F., Markovic, S. N., Molina, J. R., Halfdanarson, T. R., Pagliaro, L. C., Chintakuntlawar, A. V., Li, R., Wei, J., Wang, L., Liu, B., Nowakowski, G. S., Wang, M. L. & Wang, Y., Aug 2020, In: JAMA Network Open. 3, 8, e2012534.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Immunotherapy 100%
  • Meta-Analysis 84%
  • Systematic Reviews 83%
  • Randomized Controlled Trials 76%
  • Survival 62%
  4 Scopus citations

• Brief Communication: Immune Checkpoint Inhibitor-induced Diaphragmatic Dysfunction: A Case Series

  Archibald, W. J., Anderson, D. K., Breen, T. J., Sorenson, K. R., Markovic, S. N. & Blauwet, L. A., Apr 1 2020, In: Journal of Immunotherapy. 43, 3, p. 104-106 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Phrenic Nerve 100%
  • Paralysis 76%
  • Dyspnea 71%
  • Communication 59%
  • Muscular Diseases 42%

• Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

  Vera Aguilera, J., Paludo, J., Mcwilliams, R. R., Zhang, H., Li, Y., Kumar, A. B., Failing, J., Kottschade, L. A., Block, M. S., Markovic, S. N., Dong, H., Dronca, R. S. & Yan, Y., Aug 1 2020, In: Melanoma research. 30, 4, p. 364-375 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Immunotherapy 100%
  • Melanoma 94%
  • Drug Therapy 33%
  • T-Lymphocytes 28%
  • Confidence Intervals 27%
  6 Scopus citations

• Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis

  Owoyemi, I., Vaughan, L. E., Costello, C. M., Thongprayoon, C., Markovic, S. N., Herrmann, J., Otley, C. C., Taner, T., Mangold, A. R., Leung, N., Herrmann, S. M. & Kukla, A., Nov 1 2020, In: Cancer. 126, 21, p. 4780-4787 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Transplant Recipients 100%
  • Transplants 67%
  • Neoplasms 34%
  • Organ Transplantation 19%
  • Heart 11%
  1 Scopus citations

• Neurologic autoimmunity and immune checkpoint inhibitors: Autoantibody profiles and outcomes

  Sechi, E., Markovic, S. N., McKeon, A., Dubey, D., Liewluck, T., Lennon, V. A., Lopez-Chiriboga, A. S., Klein, C. J., Mauermann, M., Pittock, S. J., Flanagan, E. P. & Zekeridou, A., Oct 27 2020, In: Neurology. 95, 17, p. E2442-E2452

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Autoantibodies 94%
  • Nervous System 83%
  • ANNA1 antibody 30%
  • Neurologic Manifestations 29%
  • amphiphysin 23%
  15 Scopus citations

• Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma

  Grewal, E. P., Erskine, C. L., Nevala, W. K., Allred, J. B., Strand, C. A., Kottschade, L. A., McWilliams, R. R., Dronca, R. S., Yakovich, A. J., Markovic, S. N. & Block, M. S., Sep 2020, In: Immunotherapy. 12, 13, p. 983-995 13 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • glucopyranosyl lipid-A 100%
  • Subunit Vaccines 61%
  • Emulsions 54%
  • Oils 50%
  • Melanoma 42%

• Public and private human T-cell clones respond differentially to HCMV antigen when boosted by CD3 copotentiation

  Becher, L. R. E., Nevala, W. K., Sutor, S. L., Abergel, M., Hoffmann, M. M., Parks, C. A., Pease, L. R., Schrum, A. G., Markovic, S. N. & Gil, D., Oct 30 2020, In: Blood Advances. 4, 21, p. 5343-5356 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cytomegalovirus 100%
  • Clone Cells 79%
  • Antigens 63%
  • T-Lymphocytes 62%
  • HLA-A2 Antigen 41%

• Recurrent checkpoint inhibitor-induced warm agglutinin autoimmune hemolytic anemia in a patient with metastatic melanoma

  Hwang, S. R., O'Dowd, T., Markovic, S. N. & Wolanskyj-Spinner, A. P., Jul 1 2020, In: American journal of hematology. 95, 7, p. E169-E171

  Research output: Contribution to journal › Letter › peer-review

  Open Access